Search in:

Expert Opinion on Biological Therapy Volume 16, 2016 - Issue 1

Submit an article Journal homepage

540

Views

CrossRef citations to date

Altmetric

Drug Evaluations

Vedolizumab for the treatment of ulcerative colitis

Neal ShahidiDivision of Gastroenterology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada

Brian BresslerDivision of Gastroenterology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada

Remo PanaccioneInflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Rm 6D32, TRW Building, 3280 Hospital Drive Northwest, Calgary, AB, CanadaT2N 4N1Correspondence[email protected]

Pages 129-135 | Published online: 09 Dec 2015

Cite this article
https://doi.org/10.1517/14712598.2016.1121231
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

Papers of special note have been highlighted as:
Google Scholar
••of considerable interest
Google Scholar
Bernstein CN, Ng SC, Lakatos PL, et al. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis. 2013;19:2001–2010.
PubMed Web of Science ®Google Scholar
Rocchi A, Benchimol EI, Bernstein CN, et al. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol. 2012;26:811–817.
PubMed Web of Science ®Google Scholar
Singh S, Al-Darmaki A, Frolkis AD, et al. Post-operative mortality among patients with inflammatory bowel diseases: A systematic review and meta-analysis of population-based studies. Gastroenterology. 2015;149;928–937.
Google Scholar
Seksik P, Sokol H, Lepage P, et al. Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:11–18.
PubMed Web of Science ®Google Scholar
Mosli MH, Rivera-Nieves J, Feagan BG. T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects. Drug. 2014;74:297–311.
PubMed Web of Science ®Google Scholar
Lennard-Jones JE, Misiewicz JJ, Connell AM, et al. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet. 1965;1:188–189.
PubMed Web of Science ®Google Scholar
Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis. Br Med J. 1959;1:387–394.
PubMed Web of Science ®Google Scholar
Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:590–599.
PubMed Web of Science ®Google Scholar
Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut. 1997;40:228–233.
PubMed Web of Science ®Google Scholar
Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:630–642.
PubMed Web of Science ®Google Scholar
Timmer A, McDonald JW, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;9:CD000478.
PubMed Web of Science ®Google Scholar
Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:36–41.
PubMed Web of Science ®Google Scholar
Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancer in patients with inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2014;109:163–169.
PubMed Web of Science ®Google Scholar
Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.
PubMed Web of Science ®Google Scholar
Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomized controlled trial. Gut. 2011;60:780–787.
PubMed Web of Science ®Google Scholar
Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–265.
PubMed Web of Science ®Google Scholar
Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85–95.
PubMed Web of Science ®Google Scholar
Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:96–109.
PubMed Web of Science ®Google Scholar
Arias MT, Vande Casteele N, Vermeire S, et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:531–538.
PubMed Web of Science ®Google Scholar
Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104:760–767.
PubMed Web of Science ®Google Scholar
Shahidi N, Fu YTN, Qian H, et al. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: A systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:2034–2042.
PubMed Web of Science ®Google Scholar
Keane J, Gerson S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent. N Engl J Med. 2001;345:1098–1104.
PubMed Web of Science ®Google Scholar
Shahidi N, Bressler B. Effective tuberculosis and hepatitis B screening prior to anti-TNF-alpha therapy; are we there yet?. Dig Dis Sci. 2014;59:507–509.
PubMed Web of Science ®Google Scholar
Berlin C, Berg EL, Briskin MJ, et al. Alpha 4 beta 7 integrin mediates lymphocyte bindings to the mucosal vascular addressin MAdCAM-1. Cell. 1993;74:185–195.
PubMed Web of Science ®Google Scholar
Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarind with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology. 1996;111:1373–1380.
PubMed Web of Science ®Google Scholar
Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375–381.
PubMed Web of Science ®Google Scholar
Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353:362–368.
PubMed Web of Science ®Google Scholar
Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N Engl J Med. 2005;352:2499–2507.
PubMed Web of Science ®Google Scholar

•• Phase I study: vedolizumab in ulcerative colitis.

Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012;18:1470–1479.
PubMed Web of Science ®Google Scholar

•• Phase II study: vedolizumab in ulcerative colitis.

Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
PubMed Web of Science ®Google Scholar

•• Phase III study: vedolizumab in ulcerative colitis.

Molodecky NA, Shoon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–64.
PubMed Web of Science ®Google Scholar
Kappelman MD, Rifas-Shiman SL, Porter C, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in United States children and adult. Gastroenterology. 2008;135:1907–1913.
PubMed Web of Science ®Google Scholar
Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.
PubMed Web of Science ®Google Scholar

•• Phase III study: vedolizumab in Crohn’s disease.

Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147:618–627.
PubMed Web of Science ®Google Scholar

•• Phase III study: vedolizumab in Crohn’s disease.

Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;160:704–711.
PubMed Web of Science ®Google Scholar
Mosli MH, MacDonald JK, Bickston SJ, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis: A Cochrane systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21:1151–1159.
PubMed Web of Science ®Google Scholar

•• Cochrane meta-analysis: vedolizumab in ulcerative colitis.

Colombel JF, Sands BE, Hanauer SB, et al. Long-term safety of vedolizumab for the treatment of ulcerative colitis or Crohn’s disease. Am J Gastroenterol. 2013;108:S502.
Google Scholar
Wang MC, Zhang LY, Han W, et al. PRISMA - efficacy and safety of vedolizumab for inflammatory bowel diseases. Medicine. 2014;93:e326.
PubMed Web of Science ®Google Scholar
Katz S, Pardi DS. Inflammatory bowel disease of the elderly: Frequently asked questions (FAQs). Am J Gastroenterol. 2011;106:1889–1897.
PubMed Web of Science ®Google Scholar
Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035–1058.
PubMed Web of Science ®Google Scholar

•• 2015 clinical practice guidelines: ulcerative colitis.

Vande Casteele N, Khanna R, Levesque BG, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease. Gut. 2015;64:1539–1545.
Web of Science ®Google Scholar
Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148:1320–1329.
PubMed Web of Science ®Google Scholar
Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther. 2015;42:188–202.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Vedolizumab for the treatment of ulcerative colitis

References

•• Phase I study: vedolizumab in ulcerative colitis.

•• Phase II study: vedolizumab in ulcerative colitis.

•• Phase III study: vedolizumab in ulcerative colitis.

•• Phase III study: vedolizumab in Crohn’s disease.

•• Phase III study: vedolizumab in Crohn’s disease.

•• Cochrane meta-analysis: vedolizumab in ulcerative colitis.

•• 2015 clinical practice guidelines: ulcerative colitis.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Vedolizumab for the treatment of ulcerative colitis

References

•• Phase I study: vedolizumab in ulcerative colitis.

•• Phase II study: vedolizumab in ulcerative colitis.

•• Phase III study: vedolizumab in ulcerative colitis.

•• Phase III study: vedolizumab in Crohn’s disease.

•• Phase III study: vedolizumab in Crohn’s disease.

•• Cochrane meta-analysis: vedolizumab in ulcerative colitis.

•• 2015 clinical practice guidelines: ulcerative colitis.

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date